| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 39.8 | 33.3 | 26.6 |
| Total income | 39.9 | 33.3 | 26.6 |
| Profit before exceptional items & tax | 6.2 | 6.0 | 4.9 |
| Profit before tax | 6.2 | 6.0 | 4.9 |
| Net profit | 4.5 | 4.5 | 3.7 |
| Operating margin | 15.5% | 18.0% | 18.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +21.60% |
|---|---|
| Net profit, quarter on quarter | +0.00% |
| Revenue, year on year | +49.60% |
BSE results filing, BSE: 543963. Figures extracted from the filing.
Shelter Pharma Ltd: key numbers
- Share price
- ₹37.25
- Market cap
- ₹62.72 Cr
- Revenue (annual)
- ₹73.13 Cr
- Net profit (annual)
- ₹9.03 Cr
- P/E (TTM)
- 7.0×Sector 50.4×
- Promoter holding
- 44.38%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shelter Pharma Ltd
All →Shelter Pharma Bags ₹0.1 Cr Order from Berlin International Company
Shelter Pharma received a ₹0.10 Cr export order from Berlin International Company for D3 CURE nutraceuticals. The order broadens its global nutraceutical customer base.
- Value
- ₹0.10 Cr
- From
- Berlin International Company
- Execution
- mutually agreed timelines as per purchase order schedule
Shelter Pharma Business Update
Shelter Pharma will participate in the Vishwa Ayurveda Parishad Exhibition in Jaipur on 17-18 September 2026. The company secured a stall to showcase its pharmaceutical and Ayurveda product portfolio.
Shelter Pharma Annual Report
Shelter Pharma Ltd has filed its 19th Annual Report for the financial year 2025-26 in compliance with SEBI (LODR) regulations.